Ortrud Uckermann1, Wenmin Yao1, Tareq A Juratli1, Roberta Galli2, Elke Leipnitz1, Matthias Meinhardt3, Edmund Koch2, Gabriele Schackert1,4, Gerald Steiner5, Matthias Kirsch6,7,8. 1. Neurosurgery, University Hospital Carl Gustav Carus, TU Dresden, Fetscherstr. 74, 01307, Dresden, Germany. 2. Department of Anesthesiology and Intensive Care Medicine, Faculty of Medicine, Clinical Sensoring and Monitoring, TU Dresden, Fetscherstr. 74, 01307, Dresden, Germany. 3. Neuropathology, University Hospital Carl Gustav Carus, TU Dresden, Dresden, Germany. 4. German Cancer Consortium (DKTK) Dresden and German Cancer Research Center (DKFZ), National Center for Tumor Diseases (NCT), Partner Site Dresden, Dresden, Germany. 5. Department of Anesthesiology and Intensive Care Medicine, Faculty of Medicine, Clinical Sensoring and Monitoring, TU Dresden, Fetscherstr. 74, 01307, Dresden, Germany. Gerald.steiner@tu-dresden.de. 6. Neurosurgery, University Hospital Carl Gustav Carus, TU Dresden, Fetscherstr. 74, 01307, Dresden, Germany. Matthias.kirsch@uniklinikum-dresden.de. 7. German Cancer Consortium (DKTK) Dresden and German Cancer Research Center (DKFZ), National Center for Tumor Diseases (NCT), Partner Site Dresden, Dresden, Germany. Matthias.kirsch@uniklinikum-dresden.de. 8. CRTD/DFG-Center for Regenerative Therapies Dresden-Cluster of Excellence, TU Dresden, Dresden, Germany. Matthias.kirsch@uniklinikum-dresden.de.
Abstract
INTRODUCTION: Mutations in the isocytrate dehydrogenase 1 (IDH1) gene are early genetic events in glioma pathogenesis and cause profound metabolic changes. Because this genotype is found in virtually every tumor cell, therapies targeting mutant IDH1 protein are being developed. The intraoperative administration of those therapies would require fast technologies for the determination of IDH1 genotype. As of today, there is no such diagnostic test available. Recently, infrared spectroscopy was shown to bridge this gap. Here, we tested Raman spectroscopy for analysis of IDH1 genotype in glioma, which constitutes an alternative contact-free technique with the potential of being applicable in situ. METHODS: Human glioma samples (n = 36) were obtained during surgery and cryosections were prepared. IDH1 mutations were assessed using DNA sequencing and 100 Raman spectra were obtained for each sample. RESULTS: Analysis of Raman spectra revealed increased intensities in spectral bands related to DNA in IDH1 mutant glioma while bands assigned to molecular vibrations of lipids were significantly decreased. Moreover, intensities of Raman bands assigned to proteins differed in IDH1 mutant and IDH1 wild-type glioma, suggesting alterations in the protein profile. The selection of five bands (498, 826, 1003, 1174 and 1337 cm-1) allowed the classification of Raman spectra according to IDH1 genotype with a correct rate of 89%. CONCLUSION: Raman spectroscopy constitutes a simple, rapid and safe procedure for determination of the IDH1 mutation that shows great promise for clinically relevant in situ diagnostics.
INTRODUCTION: Mutations in the isocytrate dehydrogenase 1 (IDH1) gene are early genetic events in glioma pathogenesis and cause profound metabolic changes. Because this genotype is found in virtually every tumor cell, therapies targeting mutant IDH1 protein are being developed. The intraoperative administration of those therapies would require fast technologies for the determination of IDH1 genotype. As of today, there is no such diagnostic test available. Recently, infrared spectroscopy was shown to bridge this gap. Here, we tested Raman spectroscopy for analysis of IDH1 genotype in glioma, which constitutes an alternative contact-free technique with the potential of being applicable in situ. METHODS:Humanglioma samples (n = 36) were obtained during surgery and cryosections were prepared. IDH1 mutations were assessed using DNA sequencing and 100 Raman spectra were obtained for each sample. RESULTS: Analysis of Raman spectra revealed increased intensities in spectral bands related to DNA in IDH1 mutant glioma while bands assigned to molecular vibrations of lipids were significantly decreased. Moreover, intensities of Raman bands assigned to proteins differed in IDH1 mutant and IDH1 wild-type glioma, suggesting alterations in the protein profile. The selection of five bands (498, 826, 1003, 1174 and 1337 cm-1) allowed the classification of Raman spectra according to IDH1 genotype with a correct rate of 89%. CONCLUSION: Raman spectroscopy constitutes a simple, rapid and safe procedure for determination of the IDH1 mutation that shows great promise for clinically relevant in situ diagnostics.
Authors: Brett E Johnson; Tali Mazor; Chibo Hong; Michael Barnes; Koki Aihara; Cory Y McLean; Shaun D Fouse; Shogo Yamamoto; Hiroki Ueda; Kenji Tatsuno; Saurabh Asthana; Llewellyn E Jalbert; Sarah J Nelson; Andrew W Bollen; W Clay Gustafson; Elise Charron; William A Weiss; Ivan V Smirnov; Jun S Song; Adam B Olshen; Soonmee Cha; Yongjun Zhao; Richard A Moore; Andrew J Mungall; Steven J M Jones; Martin Hirst; Marco A Marra; Nobuhito Saito; Hiroyuki Aburatani; Akitake Mukasa; Mitchel S Berger; Susan M Chang; Barry S Taylor; Joseph F Costello Journal: Science Date: 2013-12-12 Impact factor: 47.728
Authors: David N Louis; Arie Perry; Guido Reifenberger; Andreas von Deimling; Dominique Figarella-Branger; Webster K Cavenee; Hiroko Ohgaki; Otmar D Wiestler; Paul Kleihues; David W Ellison Journal: Acta Neuropathol Date: 2016-05-09 Impact factor: 17.088
Authors: Dan Rohle; Janeta Popovici-Muller; Nicolaos Palaskas; Sevin Turcan; Christian Grommes; Carl Campos; Jennifer Tsoi; Owen Clark; Barbara Oldrini; Evangelia Komisopoulou; Kaiko Kunii; Alicia Pedraza; Stefanie Schalm; Lee Silverman; Alexandra Miller; Fang Wang; Hua Yang; Yue Chen; Andrew Kernytsky; Marc K Rosenblum; Wei Liu; Scott A Biller; Shinsan M Su; Cameron W Brennan; Timothy A Chan; Thomas G Graeber; Katharine E Yen; Ingo K Mellinghoff Journal: Science Date: 2013-04-04 Impact factor: 47.728
Authors: Stefan Pusch; Sonja Krausert; Viktoria Fischer; Jörg Balss; Martina Ott; Daniel Schrimpf; David Capper; Felix Sahm; Jessica Eisel; Ann-Christin Beck; Manfred Jugold; Viktoria Eichwald; Stefan Kaulfuss; Olaf Panknin; Hartmut Rehwinkel; Katja Zimmermann; Roman C Hillig; Judith Guenther; Luisella Toschi; Roland Neuhaus; Andrea Haegebart; Holger Hess-Stumpp; Markus Bauser; Wolfgang Wick; Andreas Unterberg; Christel Herold-Mende; Michael Platten; Andreas von Deimling Journal: Acta Neuropathol Date: 2017-01-25 Impact factor: 15.887
Authors: Damon DePaoli; Émile Lemoine; Katherine Ember; Martin Parent; Michel Prud'homme; Léo Cantin; Kevin Petrecca; Frédéric Leblond; Daniel C Côté Journal: J Biomed Opt Date: 2020-05 Impact factor: 3.170
Authors: Laurent James Livermore; Martin Isabelle; Ian Mac Bell; Connor Scott; John Walsby-Tickle; Joan Gannon; Puneet Plaha; Claire Vallance; Olaf Ansorge Journal: Neurooncol Adv Date: 2019-05-28
Authors: Nicolas Neidert; Jakob Straehle; Daniel Erny; Vlad Sacalean; Amir El Rahal; David Steybe; Rainer Schmelzeisen; Andreas Vlachos; Peter Christoph Reinacher; Volker Arnd Coenen; Boris Mizaikoff; Dieter Henrik Heiland; Marco Prinz; Jürgen Beck; Oliver Schnell Journal: Neurosurg Rev Date: 2021-12-16 Impact factor: 3.042
Authors: Todd C Hollon; Balaji Pandian; Esteban Urias; Akshay V Save; Arjun R Adapa; Sudharsan Srinivasan; Neil K Jairath; Zia Farooq; Tamara Marie; Wajd N Al-Holou; Karen Eddy; Jason A Heth; Siri Sahib S Khalsa; Kyle Conway; Oren Sagher; Jeffrey N Bruce; Peter Canoll; Christian W Freudiger; Sandra Camelo-Piragua; Honglak Lee; Daniel A Orringer Journal: Neuro Oncol Date: 2021-01-30 Impact factor: 12.300